問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2019-03-18 - 2024-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-07-01 - 2027-05-30

Phase I/II

Active
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Condition/Disease

    large granular lymphocyte

  • Test Drug

    DR-01

Participate Sites
2Sites

Not yet recruiting2Sites

2023-07-01 - 2027-12-31

Phase II

Active
A Randomized, Double-Blinded, Vehicle-Controlled, Parallel, Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 (rhNEGF) for the Treatment of Diabetic Lower Leg and Foot Ulcers

  • Condition/Disease

    Diabetic

  • Test Drug

    solution

Participate Sites
5Sites

Recruiting5Sites

2026-04-17 - 2028-08-02

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2023-07-31 - 2026-04-19

Others

Active
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES

  • Condition/Disease

    Breast Cancer 、Head and Neck Cancer

  • Test Drug

    膠囊劑 錠劑

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2022-05-02 - 2027-03-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2021-09-01 - 2025-04-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2024-11-01 - 2031-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    錠劑 軟膠囊劑

Participate Sites
5Sites

Recruiting5Sites

2025-08-01 - 2035-08-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)

  • Condition/Disease

    Metastatic Castration Sensitive Prostate Cancer (mCSPC)

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    錠劑 軟膠囊劑 輸注液

Participate Sites
6Sites

Recruiting6Sites

1 5 6 7 8 9 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB